January 2025 – Page 20

Breakthrough in Graft-Versus-Host Disease Treatment: MaaT013 Microbiome Therapy Shows Unprecedented Efficacy

4 months ago talkbio0Tagged acute, Fecal Microbiota Transplantation, Graft-Versus-Host Disease, GvHD, MaaT013, Microbiome Therapy, Precision - temporal, Science of nutrition, Steroid-Resistant

Graft-Versus-Host Disease (GvHD), Microbiome Therapy, MaaT013, Acute GvHD, Steroid-Resistant GvHD, Faecal Microbiota Transplantation, Precision Nutrition

Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102

4 months ago talkbio0Tagged Antipsychotic Agents, benzamide, LB-102, Pharma, Phase 2 Clinical Trials, Pounds, Schizophrenia

LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics

Transcarent Acquires Accolade for $621 Million in Strategic Healthcare Deal

4 months ago talkbio0Tagged Accolade, AI-powered, Health care facility, healthcare acquisition, Healthcare technology, Transcarent

Transcarent, Accolade, healthcare acquisition, personalized healthcare, AI-powered healthcare, healthcare technology

Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories

4 months ago talkbio0Tagged Biotechnology, Crown Laboratories, Industry, Revance, sulfanilamide, Teoxane

Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry

FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines

4 months ago talkbio0Tagged Abrysvo, Arexvy, Cautionary Warning, Guillain-Barré syndrome, Pfizer, Respiratory syncytial virus, SmithKline Beecham, United States Food and Drug Administration, Vaccines

RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy

Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment

4 months ago talkbio0Tagged Arch of foot, Denali, F-Prime Capital, Mubadala, Neurological diseases, Partner in relationship, small molecule therapies, Tenvie, venture

Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital

Fierce Health Payer Summit 2025: Shaping the Future of Healthcare Payers

4 months ago talkbio0Tagged Behavior, Fierce, Health, Health Payer Summit, Healthcare Industry, Healthcare Payers, payer-provider alignment, trends qualifier, Value-Based Care

Fierce Health Payer Summit, healthcare payers, value-based care, behavioral health, payer-provider alignment, healthcare industry trends.

Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations

4 months ago talkbio0Tagged benefit-sharing program, Bio, Diversity, Genetic Research, geographic population, Metabolic Diseases, Nordisk, Variant, VB-Inference platform

Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program

FDA Updates Label for Agios’ PYRUKYND with New Liver Injury Warning

4 months ago talkbio0Tagged Agios, Cautionary Warning, Injury of liver, label update, Pyrukynd, Thalassemia, United States Food and Drug Administration

Agios Pharmaceuticals, PYRUKYND, mitapivat, liver injury warning, FDA label update, thalassemia treatment

Sanofi Partners with Alloy Therapeutics in $400M Deal to Advance Antisense Therapeutics

4 months ago talkbio0Tagged Alloys, Antisense, biobucks, Genetic Medicine, sanofi

Sanofi, Alloy Therapeutics, Antisense Therapeutics, Biobucks Deal, Genetic Medicine